How Scarcity Inverts the Traditional Sponsor-Site Partnership Dynamic and the Impact on Patient Enrollment

Session details:

The April 18, 2026 Executive Order on psychedelics, combined with Texas’s $50M ibogaine research consortium, is driving a surge of Schedule I trials into a tiny pool of capable sites. This session unpacks how that scarcity inverts the traditional sponsor-site partnership dynamic, and what the inversion reveals about patient enrollment and retention that applies far beyond psychedelics.

Attendees will walk away with a practical view of what partnership looks like when patients are calling sites unprompted, when dosing days run 8 to 12 hours, and when the factors that drive retention have almost nothing to do with reminder texts and stipends. More specifically:  

• The real mechanics behind an 88% enrollment rate in CNS  
• How a single independent site competes for patient attention against large psychiatric networks in the same metro  
• The unglamorous infrastructure behind 90% retention: medical record retrieval, coordinator continuity, communication cadences, and the judgment calls SOPs don't cover  
• Where the industry's conventional wisdom is on paid media and diversity enrollment actually holding up, and where it doesn't  
• The reality of how important partnership models are for retention, for example logistics vs the therapeutic alliance